Intuitive Surgical stock holds a $133 billion valuation as Q2 2026 growth supports demand
Published on 08/28/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (US46120E6023) stock is trading in the mid-$360 range on its Nasdaq listing as of August 28, 2026, supported by double-digit revenue and earnings growth from its latest reported quarter and a valuation backdrop anchored by a market capitalization above $130 billion.
Per recent market data as of August 28, 2026, one intraday snapshot shows Intuitive Surgical stock changing hands at $370.11, up 1.21% from a prior close at $367.07, while another cites a latest quote of $367.33 alongside a market cap of $133.2 billion and trading volume near 949,300 shares.
On the fundamentals side, recent coverage of the company’s second-quarter 2026 performance highlights that revenue reached $2.89 billion and quarterly earnings per share came in at $2.80, with revenue growth running above the mid-teens year-over-year and earnings beating consensus estimates for the period.
Q2 2026 earnings deliver double-digit growth
Recent analysis of Intuitive Surgical’s Q2 2026 results notes that the company reported quarterly revenue of $2.89 billion, which was ahead of analyst expectations for the period and reflected year-over-year growth in the high-teens percentage range.
In the same Q2 2026 snapshot, the company delivered earnings per share of $2.80, outpacing a consensus estimate of $2.48 by $0.32 and marking a significant improvement versus the $1.81 per share reported in the prior-year quarter.
The reported Q2 2026 figures also show that Intuitive Surgical generated a net margin of 28.45% and a return on equity approaching 17%, underlining that the growth in robotic-assisted procedures is feeding through into strong profitability and cash generation across the business.
Procedure growth and international expansion support outlook
Beyond headline earnings, recent breakdowns of Intuitive Surgical’s Q2 2026 performance emphasize that surgical procedure volumes associated with its robotic platforms continued to climb, with total procedures rising 16% compared with the same quarter a year earlier.
Within that total, international da Vinci procedures increased 20% year-over-year in Q2 2026, signaling that hospitals outside the United States are stepping up adoption of robotic-assisted surgery, which in turn supports recurring revenue from instruments and accessories.
The company’s newer platforms also contributed meaningfully to growth in the quarter, with single-port procedures advancing 61% year-over-year and Ion lung biopsy procedures up 36%, highlighting how Intuitive Surgical is broadening its addressable market across different surgical specialties.
For full-year 2026, equities analysts collectively anticipate that Intuitive Surgical will post earnings per share of 8.87, based on recent consensus figures, which implies that the company is expected to sustain elevated profitability beyond the strong Q2 2026 showing.
Valuation, consensus targets, and institutional backing
On the market side, Intuitive Surgical’s valuation context as of late August 2026 is framed by a market capitalization around $131.97 billion to $133.2 billion, depending on the specific snapshot, at share prices in the high-$300s to mid-$500s cited across recent intraday and closing data.
A recent Nasdaq close at $371.67 on August 25, 2026, combined with a latest quote around $367 to $370 as of August 28, 2026, places Intuitive Surgical stock well below its 52-week high of $603.88, while still comfortably above its 52-week low of $328.57.
The spread between the current trading zone and the 52-week high suggests that shares would need to advance more than 60% from a $367 level to revisit that peak, indicating room for potential upside if earnings and procedure growth remain robust.
Recent analyst data compiled across coverage shows that Intuitive Surgical carries an average rating described as Moderate Buy, with an average published price target of $508.68, implying a double-digit percentage gap between consensus valuation and the latest trading levels in the mid-$360s.
Institutional investors play a significant role in the shareholder base, with recent figures indicating that institutional holders collectively own 83.64% of the company’s outstanding stock, underscoring that professional investors remain heavily engaged.
Robotic platforms: da Vinci and Ion at the center
Intuitive Surgical’s business is built around designing, manufacturing, and servicing robotic-assisted surgical systems, with the da Vinci family of platforms representing its flagship offering across a wide range of minimally invasive procedures.
The latest generation of the platform, often referred to in coverage as da Vinci 5, is being deployed through both new system placements and upgrades of existing installations, with recent commentary highlighting that the company is channeling record free cash flow into accelerating more than 100 upgrades of installed systems.
Da Vinci systems enable surgeons to perform complex procedures with enhanced visualization, precision, and control, while hospitals typically generate recurring demand for Intuitive Surgical’s instruments and accessories as procedure volumes grow, creating a durable revenue stream over time.
Alongside da Vinci, the Ion system is focused on robotic-assisted bronchoscopy and lung biopsy procedures, an area where Intuitive Surgical is working to expand its presence as physicians seek more accurate and less invasive diagnostic options for pulmonary nodules.
The reported Q2 2026 growth rates for single-port and Ion procedures, at 61% and 36% year-over-year respectively, show that these newer platforms are scaling rapidly from a smaller base and could contribute an increasing share of overall procedure growth in future periods.
Shares trade in the high-$360s as of the latest session
As of an intraday snapshot on August 28, 2026, Intuitive Surgical stock is quoted at $370.11 on its Nasdaq listing, representing a 1.21% increase compared with a prior close at $367.07 and reflecting ongoing investor willingness to pay a premium multiple for the company’s growth profile.
Other recent market data for the same date cite a latest quote of $367.33 alongside a market cap of $133.2 billion and volume of 949,300 shares, showing that liquidity in the stock remains strong and that trading activity is consistent with a large-cap healthcare technology name.
From a longer-term perspective, the 52-week low of $328.57 and 52-week high of $603.88 provide a wide band of historical trading levels, with the current price zone in the high-$360s situated closer to the low end than the peak, underscoring how previous enthusiasm for the stock at over $600 has moderated in 2026.
Read more on Intuitive Surgical stock
Recent coverage of Intuitive Surgical stock and Q2 2026 metrics provides additional detail on how the company’s revenue, earnings, and procedure growth trends intersect with valuation and analyst expectations.
A recent institutional ownership and earnings overview sets out the latest quarterly figures, consensus earnings expectations, and the extent of professional investor participation in the stock.
An analysis of Intuitive Surgical’s use of record free cash flow discusses how the company is investing in more than 100 da Vinci 5 upgrades and what that may mean for future procedure volumes and recurring revenue.
Da Vinci 5 upgrades highlight product strategy
Within Intuitive Surgical’s product portfolio, the ongoing rollout of da Vinci 5 upgrades has emerged as a key strategic initiative, with recent commentary indicating that the company is directing record free cash flow toward accelerating more than 100 such upgrades at customer sites.
These upgrades typically involve enhancing imaging, ergonomics, and instrument capabilities on installed systems, allowing surgeons to access new features without hospitals needing to invest in entirely new platforms, which can make capital planning more flexible.
By upgrading installed systems to the latest generation, Intuitive Surgical also reinforces its ecosystem of instruments and accessories, as newer features may encourage higher utilization and expanded procedure types, thereby supporting recurring revenue streams tied to surgical volume.
For patients, the continued evolution of da Vinci technology aims to translate into less invasive procedures, shorter hospital stays, and lower complication rates, while surgeons benefit from improved visualization and dexterity during operations.
Stock valuation and investor takeaway
At a recent intraday quote of $370.11 as of August 28, 2026, against an average published analyst price target of $508.68, Intuitive Surgical stock trades at a level that is meaningfully below the consensus valuation, suggesting that the market has not fully priced in the expected earnings trajectory if consensus proves accurate.
The combination of Q2 2026 revenue of $2.89 billion, earnings per share of $2.80, total procedure growth of 16% year-over-year, and strong adoption of newer platforms such as single-port and Ion provides a quantitative foundation for the company’s long-term growth narrative in robotic-assisted surgery.
For investors, the wide gap between the current price in the high-$360s and the 52-week high of $603.88, alongside the multi-hundred-dollar consensus target, highlights both the potential for future gains if execution remains strong and the need to weigh valuation against competitive and regulatory risks typical for advanced medical technology businesses.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 28, 2026, 2:19 p.m. ET): $370.11 USD
Market cap: $133.2 billion (as of August 28, 2026)
Sector / Industry: Health Care / Health Care Equipment
Index membership: S&P 500
